What is the ticker symbol for Infinity Pharmaceuticals?

Infinity Pharmaceuticals trades under the ticker INFI on NASDAQ.

What sector does Infinity Pharmaceuticals operate in?

Infinity Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze INFI in a portfolio?

PortView shows INFI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Infinity Pharmaceuticals (INFI) Stock Analysis

NASDAQHealthcareBiotechnology

$0.01-52.38%

1-year price historyRange $0.00 – $1.26

52-week range$0.01

$0.01$1.30

What Infinity Pharmaceuticals does

Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge, Massachusetts, operates as a biopharmaceutical firm dedicated to creating innovative therapies for individuals battling cancer. A central component of its pipeline is IPI-549, an experimental immuno-oncology drug taken orally. This candidate, currently in clinical development, functions by blocking the phosphoinositide-3-kinase-gamma enzyme. IPI-549 is undergoing Phase 2 trials for metastatic triple negative breast cancer and urothelial cancer, and Phase 1/1b trials for various solid tumors. The company maintains several strategic partnerships: with Intellikine, Inc. for the discovery, development, and commercialization of PI3K delta and/or gamma isoform-targeting pharmaceuticals; with Verastem, Inc. for the research, development, commercialization, and production of duvelisib and related compounds; and with PellePharm, Inc. to advance and commercialize its hedgehog inhibitor program, IPI-926, which is also a clinical-stage investigational drug. Furthermore, Infinity Pharmaceuticals holds collaborative agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company.

Key metrics

Market cap

$726,089

P/E (TTM)

-0.02

EPS (TTM)

$-0.44

Beta

1.38

Dividend yield

0.00%

Revenue / share

$0.03

50-day avg

$0.09

200-day avg

$0.26

52-week high

$1.30

52-week low

$0.01

CEO

Seth A. Tasker

ETFs linked to INFI

Broad-market and Healthcare sector ETFs an investor holding Infinity Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how INFI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze INFI in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Infinity Pharmaceuticals?: Infinity Pharmaceuticals trades under the ticker INFI on NASDAQ.
Which exchange is INFI listed on?: INFI is listed on NASDAQ.
What sector does Infinity Pharmaceuticals operate in?: Infinity Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze INFI in a portfolio?: PortView shows INFI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.